Microcap Ledger iBio, Inc. $IBIO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Fiscal year end
- June 30
- Shares outstanding
- 64,307,256 [10-K 2026-08-28]
What the company doesAI summary of filing
iBio, Inc. is a clinical-stage biotechnology company developing antibody therapeutics using artificial intelligence for obesity, cardiometabolic, and cardiopulmonary diseases. The company generates revenue through its AI Drug Discovery Platform by licensing technology to partners and receives milestone payments and sublicense fees. iBio is advancing IBIO-600 (a myostatin antibody) through a Phase 1 clinical trial initiated in June 2026, with IBIO-610 (an Activin E antibody) and IBIO-800 (a bispecific antibody) in preclinical development, along with programs in immuno-oncology available for partnering. [10-K 2026-08-28]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| FY ended Jun 2026 | $100.0K | −$32.84M | −$23.22M | $56.40M | [10-K 2026-08-28] |
| FY ended Jun 2025 | $400.0K | −$18.38M | −$15.30M | $8.58M | [10-K 2026-08-28] |
- Quarterly cash burn
- −$5.80M
- Cash runway Estimate
- ~29.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 9,149,470 | [10-Q 2024-11-12] |
| 2025-02-07 | 9,874,676 | [10-Q 2025-02-10] |
| 2025-05-01 | 16,519,281 | [10-Q 2025-05-02] |
| 2025-09-04 | 19,654,636 | [10-K 2025-09-05] |
| 2025-11-10 | 22,487,308 | [10-Q/A 2025-11-17] |
| 2026-02-09 | 34,543,561 | [10-Q 2026-02-10] |
| 2026-05-12 | 49,678,561 | [10-Q 2026-05-12] |
| 2026-08-27 | 64,307,256 | [10-K 2026-08-28] |
- Shelf registration
- S-3 filed 2026-02-27; declared effective 2026-03-06 [S-3 2026-02-27]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-08-01. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-08-01 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-01] |
| 2025-02-19 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-19] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-03-26 | Banjak Marc | buy | 12,500 | $1.64 | [4 2026-03-27] |
| 2026-03-26 | Banjak Marc | buy | 1,434 | $1.76 | [4 2026-03-27] |
| 2026-03-19 | Duran Felipe | buy | 24,835 | $2.02 | [4 2026-03-23] |
| 2026-03-19 | Brenner Martin | buy | 12,336 | $2.02 | [4 2026-03-23] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-14 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-04 | DEF 14A | Proxy statement |
| 2026-08-28 | 10-K | Annual report |
| 2026-08-28 | 8-K | Results of operations |
| 2026-08-20 | PRE 14A | Proxy statement |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 8-K | Director or officer change; Other events |
| 2026-07-17 | 8-K | Other events |
| 2026-07-01 | 8-K | Regulation FD disclosure; Other events |
Alerts for $IBIO
Email me when iBio, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.